PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Go online to PeerView.com/CAV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an immuno-oncology expert describes the benefits and limitations of available immune checkpoint inhibitors, investigational immunotherapies, and rational combinations that may expand the therapeutic landscape for various malignancies, and explains how to integrate the latest immunotherapy approaches into cancer care in the context of clinical practice or ongoing studies. Upon completion of this activity, participants should be better able to: Summarize the benefits and limitations of available immune checkpoint inhibitors and the need for novel immunotherapies and combinations to optimize outcomes for patients with cancer, Discuss investigational immunotherapies and rational combinations that may be able to expand on the current therapies or overcome immune evasion and resistance, Integrate the latest immunotherapy approaches into cancer care in the context of clinical practice or clinical trials.

Go online to PeerView.com/RZD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in ophthalmology discusses improving patient outcomes in neovascular age-related macular degeneration. Upon completion of this activity, participants should be better able to: Recognize the burden associated with conventional anti-VEGF treatment regimens for neovascular AMD, Assess the latest clinical data (eg, efficacy, safety, maximum effective dosing interval) for approved neovascular AMD treatment regimens, Apply individualized treatment plans for patients with neovascular AMD, Identify clinical strategies to assess for and manage rare adverse events associated with anti-VEGF therapies.

Go online to PeerView.com/NBT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in COPD discusses evidence-based guidelines to diagnose and treat COPD, as well as multidisciplinary strategies to increase adherence to treatment. Upon completion of this activity, participants will be able to: Employ evidence-based guidelines to diagnose patients with chronic obstructive pulmonary disease (COPD), Create treatment plans for patients with COPD according to evidence-based guidelines to minimize exacerbation risk, preserve lung function, and improve quality of life, Discuss opportunities for members of the healthcare team to improve care for patients with COPD and minimize time constraints on primary care physicians, Apply strategies for patients to become more engaged in their care to improve adherence to treatment regimens.

Go online to PeerView.com/BTV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Multiple sclerosis (MS) is associated with complex pathophysiology and numerous management challenges, resulting in the need for a full and diverse range of treatment options. Bruton tyrosine kinase (BTK) inhibitors hinder actions of B cells and resident CNS innate immune cells (microglia) that can contribute to neuroinflammation and neurodegeneration and ultimately lead to disease progression and disability. Based on these mechanisms, BTK inhibitors have the potential to improve outcomes related to inflammation and neurodegeneration. In this PeerView educational activity based on a recent live web broadcast, our experts offer insights into the rationale for using BTK inhibitors to treat MS, current evidence regarding the use of BTK inhibitors in the treatment of MS, and the potential role of BTK inhibitors for individualized MS management based on available evidence and patient characteristics. Upon completion of this activity, participants should be better able to: Recognize the rationale for using Bruton tyrosine kinase (BTK) inhibitors to treat multiple sclerosis (MS), Summarize current evidence regarding the use of BTK inhibitors in the treatment of MS, Assess the potential role of BTK inhibitors for individualized MS management based on available evidence and patient characteristics.

Go online to PeerView.com/ZWU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients with atherosclerotic cardiovascular disease (ASCVD) are at high risk for future CV events. Hence, interventions such as lowering levels of low-density lipoprotein cholesterol (LDL-C) are indicated for reducing the risk of CV events and, in some populations, to reduce all-cause mortality. Despite the availability of national guidelines to inform the safe and effective use of lipid-lowering therapies, many patients with high-risk ASCVD fail to achieve their targeted LDL-C levels, especially in statin-treated or statin-intolerant high-risk patient populations. At a recent live web broadcast, a multidisciplinary panel of experts discussed the current perspectives and guidelines on hyperlipidemia management, explored the emerging role of newer nonstatin therapies including PCSK9-targeting agents, and gave practical insights on the possible use of these novel lipid-lowering agents to manage hyperlipidemia in high-risk patients with ASCVD. If you couldn't watch the live event, catch up with this on-demand version now! Upon completion of this activity, participants will be able to:Summarize recommendations offered in current treatment guidelines for the management of hyperlipidemia, both for primary and secondary prevention of cardiovascular events in patients with ASCVD, Assess available efficacy and safety data for current and emerging non-statin lipid-lowering agents in the setting of ASCVD, especially in patients on maximally tolerated doses of statin or statin-intolerant patients, Describe the mechanisms of action for newer lipid-lowering therapies to optimize treatment for patients on maximally tolerated doses of statin or statin-intolerant patients, Incorporate newer lipid-lowering therapies, alone or in combination, as appropriate, to provide guideline-directed LDL-C reduction and cardiovascular risk reduction in patients with high-risk ASCVD.

Go online to PeerView.com/MHP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in anticoagulation and bleeding mitigation discuss evidence-based strategies for safe reversal of direct oral anticoagulant (DOAC) therapy.Upon completion of this activity, participants should be better able to: Review current guidance regarding appropriate and safe reversal of DOACs, Explain the mechanisms of action of current and emerging DOAC reversal agents and universal antidotes to factor Xa inhibitors, Critically evaluate recent clinical evidence regarding the efficacy and safety data pertaining to the use of current and emerging DOAC reversal agents.

Go online to PeerView.com/MUD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on the management of multiple sclerosis (MS) in women discusses current perspectives on the treatment of MS in women of childbearing age, including the appropriate use of disease-modifying therapies (DMTs) before, during, and after pregnancy. Upon completion of this activity, participants should be better able to: Apply current guidelines, expert recommendations, and evidence for the management of MS in women before, during, and after pregnancy, Describe the influence of MS on pregnancy (eg, pregnancy outcomes) and of pregnancy on MS (eg, disease progression), Assess the safety and efficacy of disease-modifying therapies (DMTs) before, during, and after pregnancy in women with MS, Incorporate shared decision-making strategies to personalize care of women with MS throughout their family planning journey.

Go online to PeerView.com/JFZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert neurologist discusses new disease-modifying therapies for multiple sclerosis. Upon completion of this activity, participants should be better able to: Apply the latest efficacy, safety, and tolerability data for approved disease-modifying therapies in individualized management of patients with multiple sclerosis, Discuss emerging data for newly approved disease-modifying therapies for the treatment of multiple sclerosis.

Go online to PeerView.com/DMW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts, an oncologist and ophthalmologist, discuss the intricacies of ocular toxicities associated with multiple myeloma and explore the importance of collaborating when managing patients who are being treated with novel therapeutics. Upon completion of this activity, participants should be better able to: Identify ocular complications associated with the use of novel therapeutic options in the myeloma treatment setting, Utilize management tools such as dry eye prophylaxis, routine eye examinations, and therapeutic dose adjustment to address ocular toxicity in patients with myeloma, Develop strategies for oncology-ophthalmology collaboration in monitoring for and managing ocular toxicity in myeloma patients.

Go online to PeerView.com/CWT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in nephrology discuss emerging evidence for improving outcomes and preventing chronic kidney disease (CKD) progression using nonsteroidal mineralocorticoid receptor antagonists. Upon completion of this activity, participants should be better able to: Apply current guidance consistent with the latest recommendations for screening, diagnosis, and treatment of patients with or at risk of developing CKD, Describe the interrelationships among CKD and other common cardiometabolic comorbidities, Evaluate the role and clinical potential of novel nonsteroidal mineralocorticoid receptor antagonists in providing renoprotection and preventing disease progression in patients diagnosed with CKD.